Samsung Bioepis Boasts Positive Data On Lucentis And Herceptin Biosimilars
Post-Hoc Analysis And Five-Year Follow-Up Data Published By Firm
Ahead of launching potentially its Lucentis biosimilar in the EU early next year, Samsung Bioepis has reported two lots of positive analysis involving its Byooviz biosimilar, at the same time as it disclosed the findings of a five-year follow-up study for its trastuzumab biosimilar, Ontruzant.
You may also be interested in...
Samsung Bioepis has celebrated the FDA’s first ever approval of an ophthalmic biosimilar with its endorsement of the firm’s Byooviz ranibizumab rival to Lucentis. The firm has also signaled a surprising expected launch date in the US, as well as offering expectations for launch in Europe where the biosimilar was also recently approved.
Regeneron Pharmaceuticals has spoken out on the implication of impending competition to Lucentis for its rival product Eylea, as the market for biosimilar Lucentis looks to form by the close of this year.
Merck & Co has launched Ontruzant, the trastuzumab biosimilar developed and manufactured by Samsung Bioepis, in the US following a staggered approval process and earlier intellectual-property hurdles. The list price discount offered by the firm puts it in the middle of the pack among the four other biosimilar players currently on the market.